journal article·2026-05

Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ

Zihan Deng, Lisen Lu, Tianbing Xu, Zhitong Zhao, Yuanyuan Geng, Li Liu, Muyang Yang, Yongfa Zheng, Yao Sun, Jonathan F. Lovell, Xuesi Chen, Jianxun Ding, Honglin Jin

Nature Nanotechnology· Volume 21· Issue 5
Publisher page

Abstract

Antigen presentation is a central component of host immune responses to cancer vaccinations; however, antigen-presenting cells often fail to promote sufficient proliferation of specific T cells, thereby restricting their efficacy. This study shows that manipulating the cholesterol levels in dendritic cell (DC) membranes could enhance the antigen-presenting capability. On the basis of this finding, we developed a membrane-cholesterol-depleting nanovaccine designed to deliver antigens to DCs and simultaneously reduce the membrane cholesterol. The direct deprivation of membrane cholesterol enhanced the contact frequency between DCs and T cells and reshaped the tumour immune microenvironment to inhibit tumourigenesis and progression in multiple tumour models. Mechanistically, the designed nanovaccines promoted immune synapse formation with CD8+ T cells and augmented T cell activation and proliferation by remodelling the cholesterol microdomains in the DC membrane and blocking efferocytosis pathways, boosting the antigen presentation capacity. The study proposes an approach to enhance the effects of vaccines by depleting cholesterol levels in antigen-presenting cell membranes.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune cells in cancer · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (21)

Show source-provided references
1. Moon, C. Y. et al. Dendritic cell maturation in cancer. Nat. Rev. Cancer 25, 225–248 (2025).10.1038/s41568-024-00787-3 ↗
2. You, Q. et al. A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Nat. Nanotechnol. 20, 1298–1311 (2025).10.1038/s41565-025-01952-x ↗
3. Zhou, J. et al. STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature 643, 519–528 (2025).10.1038/s41586-025-09000-3 ↗
4. Shapir Itai, Y. et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell 187, 375–389.e318 (2024).10.1016/j.cell.2023.12.011 ↗
5. Eweje, F. et al. Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02664-2 (2025).10.1038/s41587-025-02664-2 ↗
6. Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498–1515.e1410 (2023).10.1016/j.ccell.2023.06.008 ↗
7. Plebanek, M. P. et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci. Immunol. 9, eadi4191 (2024).10.1126/sciimmunol.adi4191 ↗
8. Calzada-Fraile, D. et al. Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+T cells. Nat. Commun. 14, 6772 (2023).10.1038/s41467-023-42480-3 ↗
9. Jacobs, C. F. et al. Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia. Cell Mol. Immunol. 22, 485–500 (2025).10.1038/s41423-025-01262-1 ↗
10. Lei, K. et al. Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy. Nat. Biomed. Eng. 5, 1411–1425 (2021).10.1038/s41551-021-00826-6 ↗
11. Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity 57, 1087–1104.e1087 (2024).10.1016/j.immuni.2024.03.021 ↗
12. Kropshofer, H. et al. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat. Immunol. 3, 61–68 (2002).10.1038/ni750 ↗
13. Geels, S. N. et al. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell 42, 1051–1066.e1057 (2024).10.1016/j.ccell.2024.05.013 ↗
14. Molino, N. M., Anderson, A. K., Nelson, E. L. & Wang, S. W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano 7, 9743–9752 (2013).10.1021/nn403085w ↗
15. Rosalia, R. A. et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 43, 2554–2565 (2013).10.1002/eji.201343324 ↗
16. Belabed, M. et al. Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer. Nat. Immunol. 26, 188–199 (2025).10.1038/s41590-024-02065-8 ↗
17. Li, B. et al. Fueling sentinel node via reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant therapy. Nat. Commun. 14, 2518 (2023).10.1038/s41467-023-38245-7 ↗
18. Shapiro, I. E. & Bassani-Sternberg, M. The impact of immunopeptidomics: from basic research to clinical implementation. Semin. Immunol. 66, 101727 (2023).10.1016/j.smim.2023.101727 ↗
19. Zeng, B. et al. Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. J. Clin. Invest. 128, 1971–1984 (2018).10.1172/JCI96791 ↗
20. Zhang, J. et al. Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy. Adv. Sci. 9, e2103444 (2022).10.1002/advs.202103444 ↗
21. Cruz, L. J. et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: a comparative study. J. Control. Release 192, 209–218 (2014).10.1016/j.jconrel.2014.07.040 ↗